AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

E. Jensen-Jarolim, H. J. Bax, R. Bianchini, S. Crescioli, T. R. Daniels-Wells, D. Dombrowicz, E. Fiebiger, H. J. Gould, S. Irshad, J. Janda, D. H. Josephs, F. Levi-Schaffer, L. O’Mahony, G. Pellizzari, M. L. Penichet, F. Redegeld, F. Roth-Walter, J. Singer, E. Untersmayr, L. VangelistaS. N. Karagiannis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

Original languageEnglish
Pages (from-to)328-340
Number of pages13
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume73
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Immune Tolerance
Hypersensitivity
Neoplasms
Tumor Escape
Immunologic Desensitization
Tumor Microenvironment
Inflammation
Research
Therapeutics

Keywords

  • allergooncology
  • allergy
  • cancer
  • oncoimmunology
  • tolerance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Jensen-Jarolim, E., Bax, H. J., Bianchini, R., Crescioli, S., Daniels-Wells, T. R., Dombrowicz, D., ... Karagiannis, S. N. (2018). AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy: European Journal of Allergy and Clinical Immunology, 73(2), 328-340. https://doi.org/10.1111/all.13311

AllergoOncology : Opposite outcomes of immune tolerance in allergy and cancer. / Jensen-Jarolim, E.; Bax, H. J.; Bianchini, R.; Crescioli, S.; Daniels-Wells, T. R.; Dombrowicz, D.; Fiebiger, E.; Gould, H. J.; Irshad, S.; Janda, J.; Josephs, D. H.; Levi-Schaffer, F.; O’Mahony, L.; Pellizzari, G.; Penichet, M. L.; Redegeld, F.; Roth-Walter, F.; Singer, J.; Untersmayr, E.; Vangelista, L.; Karagiannis, S. N.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 2, 01.02.2018, p. 328-340.

Research output: Contribution to journalArticle

Jensen-Jarolim, E, Bax, HJ, Bianchini, R, Crescioli, S, Daniels-Wells, TR, Dombrowicz, D, Fiebiger, E, Gould, HJ, Irshad, S, Janda, J, Josephs, DH, Levi-Schaffer, F, O’Mahony, L, Pellizzari, G, Penichet, ML, Redegeld, F, Roth-Walter, F, Singer, J, Untersmayr, E, Vangelista, L & Karagiannis, SN 2018, 'AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer', Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 2, pp. 328-340. https://doi.org/10.1111/all.13311
Jensen-Jarolim E, Bax HJ, Bianchini R, Crescioli S, Daniels-Wells TR, Dombrowicz D et al. AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy: European Journal of Allergy and Clinical Immunology. 2018 Feb 1;73(2):328-340. https://doi.org/10.1111/all.13311
Jensen-Jarolim, E. ; Bax, H. J. ; Bianchini, R. ; Crescioli, S. ; Daniels-Wells, T. R. ; Dombrowicz, D. ; Fiebiger, E. ; Gould, H. J. ; Irshad, S. ; Janda, J. ; Josephs, D. H. ; Levi-Schaffer, F. ; O’Mahony, L. ; Pellizzari, G. ; Penichet, M. L. ; Redegeld, F. ; Roth-Walter, F. ; Singer, J. ; Untersmayr, E. ; Vangelista, L. ; Karagiannis, S. N. / AllergoOncology : Opposite outcomes of immune tolerance in allergy and cancer. In: Allergy: European Journal of Allergy and Clinical Immunology. 2018 ; Vol. 73, No. 2. pp. 328-340.
@article{c1f28c297d4e4dc39fd1dade08044e8b,
title = "AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer",
abstract = "While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.",
keywords = "allergooncology, allergy, cancer, oncoimmunology, tolerance",
author = "E. Jensen-Jarolim and Bax, {H. J.} and R. Bianchini and S. Crescioli and Daniels-Wells, {T. R.} and D. Dombrowicz and E. Fiebiger and Gould, {H. J.} and S. Irshad and J. Janda and Josephs, {D. H.} and F. Levi-Schaffer and L. O’Mahony and G. Pellizzari and Penichet, {M. L.} and F. Redegeld and F. Roth-Walter and J. Singer and E. Untersmayr and L. Vangelista and Karagiannis, {S. N.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/all.13311",
language = "English",
volume = "73",
pages = "328--340",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Blackwell",
number = "2",

}

TY - JOUR

T1 - AllergoOncology

T2 - Opposite outcomes of immune tolerance in allergy and cancer

AU - Jensen-Jarolim, E.

AU - Bax, H. J.

AU - Bianchini, R.

AU - Crescioli, S.

AU - Daniels-Wells, T. R.

AU - Dombrowicz, D.

AU - Fiebiger, E.

AU - Gould, H. J.

AU - Irshad, S.

AU - Janda, J.

AU - Josephs, D. H.

AU - Levi-Schaffer, F.

AU - O’Mahony, L.

AU - Pellizzari, G.

AU - Penichet, M. L.

AU - Redegeld, F.

AU - Roth-Walter, F.

AU - Singer, J.

AU - Untersmayr, E.

AU - Vangelista, L.

AU - Karagiannis, S. N.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

AB - While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

KW - allergooncology

KW - allergy

KW - cancer

KW - oncoimmunology

KW - tolerance

UR - http://www.scopus.com/inward/record.url?scp=85040675651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040675651&partnerID=8YFLogxK

U2 - 10.1111/all.13311

DO - 10.1111/all.13311

M3 - Article

C2 - 28921585

AN - SCOPUS:85040675651

VL - 73

SP - 328

EP - 340

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 2

ER -